Ken Griffin’s Unicycive Therapeutics UNCY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.56M Sell
236,841
-21,460
-8% -$141K ﹤0.01% 6635
2025
Q4
$1.49M Buy
258,301
+216,627
+520% +$1.16M ﹤0.01% 6525
2025
Q3
$182K Buy
+41,674
New +$182K ﹤0.01% 11357
2024
Q2
Sell
-6,940
Closed -$95.8K 15458
2024
Q1
$95.8K Buy
6,940
+3,398
+96% +$41.2K ﹤0.01% 11425
2023
Q4
$30.7K Buy
+3,542
New +$23.2K ﹤0.01% 12249
2022
Q3
Sell
-1,521
Closed -$13K 13650
2022
Q2
$13K Sell
1,521
-2,199
-59% -$21K ﹤0.01% 12526
2022
Q1
$48K Buy
+3,720
New +$54.5K ﹤0.01% 12819

Other funds holding UNCY

Ken Griffin's UNCY Position: Q1 2026 in Review

Ken Griffin reduced its Unicycive Therapeutics (UNCY) stake by 8.3% in Q1 2026, selling an estimated $141K and leaving 236,841 shares worth $1.56M. The position accounts for ﹤0.01% of the portfolio, ranked #6635.

Ken Griffin first reported a position in UNCY in Q1 2022 and has held it in 7 quarters since. 51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

  • Ken Griffin held 236,841 shares of Unicycive Therapeutics worth $1.56M as of Q1 2026.
  • Ken Griffin sold 21,460 Unicycive Therapeutics shares in Q1 2026, an estimated $141K.
  • Unicycive Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #6635 holding.
  • Ken Griffin first reported a position in Unicycive Therapeutics in Q1 2022 and has held it in 7 quarters since.
  • 51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.